IGY Immune Technology to produce purified IgY products

The company plans to begin the production by the end of 2012.

IGY Immune Technology chief executive officer Terry Dyck said, "The production of IgY at higher purity levels and lower cost will create a number of product development opportunities across the nutrition, cosmetic, pharmaceutical and animal health industries."

"We’re establishing ourselves already with leading companies that have been following IgY developments," Dyck added.

"We’re moving forward in securing these partnerships as well as providing a profitable opportunity for investors."

The company will produce commercial quantities of IgY from chicken egg yolk and the production process involves no toxic chemicals usage.